Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

Journal of Clinical Oncology

Volumn 29, Issue 12, 2011, Pages 1627-1633

  Paiva, Bruno ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Martinez Lopez, Joaquin ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Vidriales, Maria Belen ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Mateos, Maria Victoria ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Montalban, Maria Angeles ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Fernandez Redondo, Elena ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Alonso, Lourdes ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Oriol, Albert ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Teruel, Ana Isabel ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   De Paz, Raquel ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Larana, José Garcia ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Bengoechea, Enrique ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Martin, Alejandro ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Mediavilla, Joaquin Diaz ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Palomera, Luis ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   De Arriba, Felipe ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Bladé, Joan ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Orfao, Alberto ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Lahuerta, Juan Jose ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Miguel, Jesus F San ^{a,b,c,d,e,f,g,h,i,j,k,l,m}  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c Centro de Investigacion del Cancer   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^l HOSPITAL MORALES MESEGUER   (Spain)

^m HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; ANALYTIC METHOD; CANCER GROWTH; CANCER PATIENT; EVALUATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOFIXATION; IMMUNOPHENOTYPING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOLOGIC TECHNIQUES; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; MALE; MULTIPLE MYELOMA; NEPHELOMETRY AND TURBIDIMETRY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPAIN; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79955048912     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.1967     Document Type: Review

References (50)

1. Durie BG, Jacobson J, Barlogie B, et al: Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in Southwest Oncology Group chemotherapy trials. J Clin Oncol 22:1857-1863, 2004 (Pubitemid 41095176)
2. Mateos MV, Oriol A, Martínez-López J, et al: Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial. Lancet Oncol 11:934-941, 2010
3. Barlogie B, Tricot G, Anaissie E, et al: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030, 2006 (Pubitemid 43357806)
4. Lokhorst HM, van der Holt B, Zweegman S, et al: A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115:1113-1120, 2010
5. Palumbo A, Gay F, Falco P, et al: Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation- maintenance in untreated multiple myeloma patients. J Clin Oncol 28: 800-807, 2010
6. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
7. Kyle RA, Leong T, Li S, et al: Complete response in multiple myeloma: Clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 106: 1958-1966, 2006 (Pubitemid 43673211)
8. Palumbo A, Bringhen S, Liberati AM, et al: Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial. Blood 112: 3107-3114, 2008
9. Facon T, Mary JY, Hulin C, et al: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 370:1209-1218, 2007 (Pubitemid 47516593)
10. Palumbo A, Falco P, Corradini P, et al: Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 25:4459-4465, 2007 (Pubitemid 350063804)
11. Wijermans P, Schaafsma M, Termorshuizen F, et al: Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study. J Clin Oncol 28:3160-3166, 2010
12. Pineda-Roman M, Zangari M, Haessler J, et al: Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: Comparison with total therapy 2. Br J Haematol 140:625-634, 2008 (Pubitemid 351300910)
13. Harousseau JL, Palumbo A, Richardson PG, et al: Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalanprednisone versus melphalan-prednisone. Blood 116: 3743-3750, 2010
14. Chanan-Khan AA, Giralt S: Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28:2612-2624, 2010
15. Harousseau JL, Attal M, Avet-Loiseau H: The role of complete response in multiple myeloma. Blood 114:3139-3146, 2009
16. Zent CS, Wilson CS, Tricot G, et al: Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 91:3518-3523, 1998 (Pubitemid 28193907)
17. BladéJ, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT-European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998 (Pubitemid 28435189)
18. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006 (Pubitemid 44264086)
19. Dispenzieri A, Kyle R, Merlini G, et al: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:215-224, 2009
20. Corradini P, Cavo M, Lokhorst H, et al: Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 102:1927-1929, 2003 (Pubitemid 37022595)
21. Ladetto M, Pagliano G, Ferrero S, et al: Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28:2077-2084, 2010
22. Liu H, Yuan C, Heinerich J, et al: Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study. Leuk Lymphoma 49:306-314, 2008 (Pubitemid 351193924)
23. Martinelli G, Terragna C, Zamagni E, et al: Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 18:2273-2281, 2000 (Pubitemid 30350220)
24. Paiva B, Vidriales MB, CerveróJ, et al: Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:4017-4023, 2008
25. Rawstron AC, Davies FE, DasGupta R, et al: Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 100:3095-3100, 2002 (Pubitemid 35217054)
26. San Miguel JF, Almeida J, Mateo G, et al: Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 99:1853-1856, 2002 (Pubitemid 34533063)
27. Sarasquete ME, García-Sanz R, González D, et al: Minimal residual disease monitoring in multiple myeloma: A comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 90:1365-1372, 2005 (Pubitemid 41503652)
28. Martínez-Sánchez P, Montejano L, Sarasquete ME, et al: Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: The prognostic impact of achieving molecular response. Br J Haematol 142:766-774, 2008
29. de Larrea CF, Cibeira MT, Elena M, et al: Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: Implications for stringent complete remission definition. Blood 114:4954-4956, 2009
30. Singhal S, Vickrey E, Krishnamurthy J, et al: The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 114:38-39, 2009
31. Hehlmann R, Hochhaus A, Baccarani M: Chronic myeloid leukaemia. Lancet 370:342-350, 2007 (Pubitemid 47094995)
32. Iacobucci I, Saglio G, Rosti G, et al: Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 12:3037-3042, 2006 (Pubitemid 43837348)
33. Fermand JP, Ravaud P, Chevret S, et al: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Upfront or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131-3136, 1998 (Pubitemid 28492319)
34. Davies FE, Forsyth PD, Rawstron AC, et al: The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 112:814-819, 2001 (Pubitemid 32222857)
35. Lenhoff S, Hjorth M, Turesson I, et al: Intensive therapy for multiple myeloma in patients younger than 60 years: Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 91:1228-1233, 2006 (Pubitemid 44408433)
36. Harousseau JL, Dimopoulos MA, Wang M, et al: Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 95:1738-1744, 2010
37. Tricot GJ: What is the significance of molecular remission in multiple myeloma? Clin Adv Hematol Oncol 5:91-95, 2007 (Pubitemid 46455266)
38. Chee CE, Kumar S, Larson DR, et al: The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood 114:2617-2618, 2009
39. Singhal S, Powles R, Milan S, et al: Kinetics of paraprotein clearance after autografting for multiple myeloma. Bone Marrow Transplant 16: 537-540, 1995
40. Davies FE, Rawstron AC, Owen RG, et al: Minimal residual disease monitoring in multiple myeloma. Best Pract Res Clin Haematol 15:197-222, 2002
41. Barlogie B, Anaissie E, Haessler J, et al: Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 113:355-359, 2008
42. Rasmussen T, Poulsen TS, HonoréL, et al: Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay. Exp Hematol 28:1039-1045, 2000
43. Martinelli G, Terragna C, Zamagni E, et al: Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 85:930-934, 2000
44. Fenk R, Ak M, Kobbe G, et al: Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Haematologica 89:557-566, 2004 (Pubitemid 38691243)
45. Lioznov M, Badbaran A, Fehse B, et al: Monitoring of minimal residual disease in multiple myeloma after allo-SCT: Flow cytometry vs PCR-based techniques. Bone Marrow Transplant 41:913-916, 2008 (Pubitemid 351761696)
46. Mason KD, Juneja S: Go with the flow for monitoring response in myeloma with minimal residual disease. Leuk Lymphoma 49:177-178, 2008 (Pubitemid 351193908)
47. Domingo E, Moreno C, Sánchez-Ibarrola A, et al: Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease. Haematologica 95:691-692, 2010
48. Pedreira CE, Costa ES, Almeida J, et al: A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders. Cytometry A 73A:1141-1150, 2008
49. Pedreira CE, Costa ES, Barrena S, et al: Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A 73:834-846, 2008
50. Paiva B, Almeida J, Pérez-Andrés M, et al: Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cellrelated disorders. Cytometry B Clin Cytom 78:239- 252, 2010